

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI – 400 001.
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

May 30, 2016

Department of Corporate Services
Corporate Relation Department
Bombay Stock Exchange Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

The Executive Director,
Ahmedabad Stock Exchange Ltd.
First Floor, Kamdhenu Complex
Opp. Sahjanand College
Panjara Pole
Ahmedabad – 380 015

BSE Script Code: 524516

Subject : Annual Audited Financial Result of the Company for the Fourth Quarter and Financial Year ended on March 31, 2016 along with Auditor's Report pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015.

Dear Sir,

As scheduled, at the meeting of Board of Directors of the Company held on Monday, May 30, 2016 at commenced at 1.00 p.m. and concluded at 2.00 p.m., the Annual Audited Financial Results of the Company for the Quarter and Financial Year ended on March 31, 2016 along with Auditor's Report pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 was approved and adopted. A copy of the same is enclosed herewith alongwith Form "A" for your kind perusal and record. Please also find enclosed the declaration as required under Regulation 33(3)(d) of SEBI(Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2016 that the Auditors opinion, in respect to the aforesaid Financial Statements, is unmodified

The said Financial Results will be released for publishing in the Newspapers.

The Meeting of the Board of Directors was concluded at 2.00 p.m.

You are hereby requested to take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully
For BACIL PHARMA LIMITED


Director



Enclosure: As above

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001.

Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

Statement of Standalone Annual Audited Financial Results for the Quarter and for the Year Ended 31st March, 2016

(₹ In Lakhs Except Shares & EPS)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31/03/2016 (Audited)	31/12/2015 (Unaudited)	31/03/2015 (Audited)	31/03/2016 (Audited)	31/03/2015 (Audited)
1	Income					
	a) Net Sales/Income from Operations	---	---	---	---	---
	b) Other Operating Income	---	---	---	---	---
	Total Income	---	---	---	---	---
2	Expenditure					
	a) Increase/decrease in stock and work in progress	---	---	---	---	---
	b) Consumption of raw materials	---	---	---	---	---
	c) Purchase of traded goods	---	---	---	---	---
	d) Employees cost	---	---	---	---	---
	e) Depreciation	0.02	0.02	0.03	0.08	0.38
	f) Other expenditure	2.91	3.14	3.29	12.88	10.87
	Total Expenditure	2.93	3.16	3.32	12.96	11.25
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	- 2.93	- 3.16	- 3.32	- 12.96	- 11.25
4	Other Income	3.35	0.45	2.82	6.25	8.07
5	Profit before Interest and Exceptional Items (3+4)	0.42	- 2.71	- 0.50	- 6.71	- 3.18
6	Interest	---	---	---	---	---
7	Profit after Interest but before Exceptional Items (5-6)	0.42	- 2.71	- 0.50	- 6.71	- 3.18
8	Exceptional items	---	---	---	---	---
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	0.42	- 2.71	- 0.50	- 6.71	- 3.18
10	Tax expense	---	---	---	---	---
11	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	0.42	- 2.71	- 0.50	- 6.71	- 3.18
12	Extraordinary Item (net of tax expense Rs.)	---	---	---	---	---
13	Net Profit(+)/ Loss(-) for the period (11-12)	0.42	- 2.71	- 0.50	- 6.71	- 3.18
14	Paid-up equity share capital (F.V. Rs.10/- per share)	589.00	589.00	589.00	589.00	589.00
15	Reserve excluding Revaluation Reserves	---	---	---	- 12.92	- 6.21
16	Earning Per Share (before & after extraordinary items) (of ₹ 10 each) – Not Annualised (in ₹) Basic & Diluted	0.01	- 0.05	- 0.01	- 0.11	- 0.05
17	Public Shareholding					
	- No. of shares	32,57,001	32,46,300	32,46,300	32,57,001	32,46,300
	- Percentage of shareholding	55.30%	55.12%	55.12%	55.30%	55.12%
18	Promoters and promoter group Shareholding					
	a) Pledged/Encumbered					
	- Number of shares	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered					
	- Number of shares	26,32,999	26,43,700	26,43,700	26,32,999	26,43,700
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	44.70%	44.88%	44.88%	44.70%	44.88%

For BACIL PHARMA LTD.



[Signature]
Director

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001.
 Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

Statement of Assets and Liabilities

(₹ In Lakhs)

Sr. No.	Particulars	As at 31 March, 2016 Audited	As at 31 March, 2015 Audited
A	EQUITY AND LIABILITIES		
1	Shareholders Funds		
	a) Share Capital	652.72	652.72
	b) Reserves and Surplus	- 12.91	- 6.21
	Subtotal Shareholders Funds	639.81	646.51
2	Non-current Liabilities		
	a) Long-term borrowings	---	---
	b) Long-term provisions	---	---
	Subtotal Non-current Liabilities	---	---
3	Current Liabilities		
	a) Short-term borrowings	27.15	14.30
	b) Trade payables	---	---
	c) Other current liabilities	1.17	1.11
	d) Short-term provisions	1.21	0.53
	Subtotal Current Liabilities	29.53	15.94
	TOTAL EQUITY AND LIABILITIES	669.34	662.45
B	ASSETS		
1	Non-current assets		
	a) Fixed assets	593.51	588.38
	b) Non-current investments	50.73	25.21
	c) Deferred tax assets (net)	---	---
	d) Long-term loans and advances	---	---
	e) Other Non current assets	---	---
	Subtotal Non-current Assets	644.24	613.59
2	Current Assets		
	a) Current Investments	---	25.52
	b) Inventories	---	---
	c) Trade receivables	---	0.36
	d) Cash and cash equivalents	2.43	1.66
	e) Short-term loans and advances	21.70	20.71
	f) Other current assets	0.97	0.61
	Subtotal Current Assets	25.10	48.86
	TOTAL ASSETS	669.34	662.45

Note:

- The above financial results for the year ended March 31, 2016 audited by the Statutory Auditors of the Company, have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at their meetings held on May 30, 2016.
- Total amount incurred and lying unallocated under the heads Capital Work in Progress & Project Preoperative Expenses including Public Issue & Preoperative Expenses since the project was conveyed, have now been allocated to Land & Building, Plant & Machinery, Share Issue Expenses & Preliminary Expenses respectively. As the Plant & Machinery is yet not put to commercial use, no depreciation is claimed.
- There are no separate reportable segments.
- There is 1 investor complaint received during the year under review, complaint was resolved.
- The figures for the Quarter ended 31/03/2016 are balancing figures between Annual Audited figures in respect of the full Financial Year and the Published Year to date figures upto the 3rd Quarter of the relevant Financial Year.

Place: Mumbai
 Dated: May 30, 2016



For BACIL PHARMA LIMITED

[Signature]
 Director

A. W. KETKAR & CO.
CHARTERED ACCOUNTANTS

4, "SOUKHYA",
Opp. B.M.C. Hospital
V. N. Purav Marg, Chunabhatti,
Mumbai 400 022

Auditor's Report on Annual Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

To
The Board of Directors
Bacil Pharma Limited

1. We have audited the accompanying statement of Annual Financial Results of Bacil Pharma Limited ('the Company') for the year ended 31st March, 2016 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. This statement has been prepared on the basis of the Annual Financial Statements. Our responsibility is to express an opinion on this statement, based on our audit of such annual financial statements, which have been prepared in accordance with the Accounting Standards specified under section 133 of the Companies Act, 2013 ('the Act') read with Rule 7 of the Companies (Accounts), Rules, 2014 and other accounting principles generally accepted in India.
2. We conducted our audit of the statement in accordance with the standards on auditing specified under section 143(10) of the Act. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the statement is free of material misstatement. An audit includes examining, on the test basis, evidence supporting the amounts disclosed in the statement. An audit also includes assessing the accounting principles used and significant estimates made by the management.

3. We believe that the audit evidences obtained by us is sufficient and appropriate to provide a reasonable basis for our opinion on the statement.
4. In our opinion and to the best of our information and according to the explanations given to us, the statement:
 - (i) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015; and
 - (ii) Gives a true and fair view of the net loss and the other financial information of the Company for the year ended 31st March, 2016.

For A. W. KETKAR & CO.
CHARTERED ACCOUNTANTS



A. W. KETKAR
Proprietor





Membership No.: 012287

Place : Mumbai
Dated: May 30, 2016

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001.
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427 Tel.: 22618452/22661541, Tel/Fax: 22618327

FORM - A

1.	Name of the Company	Bacil Pharma Limited
2.	Annual Financial Statements for the Year ended	31 March, 2016
3.	Type of Audit observation	Un-Modified
4.	Frequency of observation	Not Applicable
5.	<u>Signed By:</u> Mr. Prakash Shah Director	
	Jayesh Ramchandra Patil Chief Finance Officer	
	Shirish Suryakant Shetye Chairman of Audit Committee	
	Statutory Auditors of the Company	For A W Ketkar & Co., Chartered Accountants FRN:105006W  A W Ketkar Proprietor Membership No.012287

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI – 400 001.

Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

DECLARATION

In respect of the Audited Financial Results for the Quarter and year ended 31st March, 2016, in terms of Regulation 33(3)(d) of the SEBI(Listing Obligations and Disclosure Requirement) (Amendments) Regulations, 2016, we hereby declares that the Auditors opinion, in respect to the aforesaid financial results, is unmodified.

For Bacil Pharma Limited



Chief Finance Officer

Place: Mumbai

Date: 30th May, 2016